Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on the Effectiveness and Safety of IMVT-1402 for Adults with Graves' Disease

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying Graves' Disease, an autoimmune condition that affects the thyroid gland, causing it to produce too much thyroid hormone. The study will evaluate a new treatment called IMVT-1402, which is administered as a solution for injection. The purpose of the study is to assess the effectiveness and safety of IMVT-1402 compared to a placebo in treating adults with Graves' Disease.

Participants in the study will receive either the new treatment, IMVT-1402, or a placebo, which looks the same but contains no active ingredients. The study will last for a period of up to 52 weeks, during which participants will be monitored to see how well the treatment works and to check for any side effects. The main goal is to see if participants can maintain normal thyroid function without the need for additional medication.

Throughout the study, participants will have regular check-ups to measure thyroid hormone levels and ensure their well-being. The study aims to provide valuable information on whether IMVT-1402 can be a safe and effective treatment option for people with Graves' Disease.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be randomly assigned to receive either the investigational medication IMVT-1402 or a placebo. A placebo looks like the investigational medication but does not contain any active ingredients.

  2. Step 2

    Medication administration

    The medication, whether IMVT-1402 or placebo, will be administered as a solution for injection under the skin, known as subcutaneous use.

  3. Step 3

    Treatment duration

    The treatment will continue for a period of 26 weeks. During this time, the effects of the medication on your condition will be closely monitored.

  4. Step 4

    Monitoring and assessments

    Throughout the study, regular assessments will be conducted to evaluate the effectiveness and safety of the treatment. These assessments will include measuring levels of certain hormones in your blood, such as T3, FT4, and TSH.

  5. Step 5

    End of treatment evaluation

    At the end of the 26-week treatment period, an evaluation will be conducted to determine if you are euthyroid, meaning your thyroid hormone levels are within the normal range, and if you can discontinue the use of antithyroid drugs (ATD).

  6. Step 6

    Follow-up period

    After the treatment period, there will be a follow-up phase to monitor your condition for an additional period, which may extend up to 52 weeks or longer, depending on your response to the treatment.

Who can join the trial?

8 criteria

  • Must be between 18 and 75 years old at the time of signing the consent form.
  • Must have a prior diagnosis of Grave's Disease.
  • Must have a TSH value (a hormone level) of less than 0.1 mIU/L as measured by the local laboratory at the screening visit.
  • Must meet one of the following conditions regarding ATD (anti-thyroid drugs) use:
    • Have been on ATD for at least 3 months before the screening visit and:
      • Currently taking ATD with a dose of at least 20 mg/day methimazole or equivalent (like 30 mg/day carbimazole or 200 mg/day propylthiouracil) for the 4 weeks before the screening visit.
      • Expected to continue on a stable dose of ATD for the 4 weeks before randomization.
      • Have been on ATD for at least 6 months before the screening visit and:
        • Have been treated with at least 15 mg/day methimazole or equivalent (like 20 mg/day carbimazole or 150 mg/day propylthiouracil) at any point during treatment history.
        • Currently taking ATD with a dose of at least 10 mg/day methimazole or equivalent (like 15 mg/day carbimazole or 100 mg/day propylthiouracil) for the 4 weeks before the screening visit.
        • Expected to continue on a stable dose of ATD for the 4 weeks before randomization.

Who cannot join the trial?

10 criteria

  • Patients with any other serious health condition that might interfere with the study.
  • Patients who are pregnant or breastfeeding.
  • Patients who have participated in another clinical trial within the last 30 days.
  • Patients with a history of drug or alcohol abuse within the past year.
  • Patients who are unable to comply with the study procedures.
  • Patients with known allergies to the study medication or its ingredients.
  • Patients with uncontrolled high blood pressure.
  • Patients with severe liver or kidney disease.
  • Patients with a history of heart disease.
  • Patients who have had a major surgery within the last 3 months.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

IMVT-1402 is a medication being studied for its potential to help treat Graves' Disease, a condition where the thyroid gland is overactive. This medication is being tested to see if it can help control the levels of certain hormones in the body, such as T3, FT3, FT4, and TSH, which are important for regulating metabolism and energy. The goal is to see if IMVT-1402 can help bring these hormone levels back to normal, which may help reduce the symptoms of Graves' Disease and improve the overall health of patients. The study is also looking at how safe and well-tolerated this medication is for people who take it.

What is already known about the treatment

IMVT-1402 – IMVT-1402 is administered as an injection and is currently being studied in clinical trials for its potential use in treating Graves' Disease, an autoimmune disorder affecting the thyroid. The medication is in the experimental phase, specifically a Phase 2b trial, which means it is being tested for its effectiveness and safety in patients. IMVT-1402 works by targeting specific proteins in the body to help regulate thyroid hormone levels, aiming to reduce symptoms associated with the disease. It falls under the category of immunomodulatory drugs, which are designed to modify the immune system's response.

Investigated diseases

Graves' Disease – Graves' Disease is an autoimmune disorder that leads to the overactivity of the thyroid gland, known as hyperthyroidism. The immune system mistakenly attacks the thyroid, causing it to produce excessive amounts of thyroid hormones. This results in symptoms such as rapid heartbeat, weight loss, increased appetite, and nervousness. As the disease progresses, individuals may experience swelling of the neck due to an enlarged thyroid gland, known as a goiter. Eye problems, such as bulging eyes or irritation, can also occur. The progression of the disease can vary, with periods of worsening symptoms and times of improvement.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-516020-33-00Protocol codeIMVT-1402-2502Estimated enrolment225 patientsSponsorImmunovant Sciences GmbH

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.